article
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
List view / Grid view
Antibody Discovery
article
New research improves the safety and effectiveness of ADC cancer treatments
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
article
New targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
news
New platform will accelerate single-cell analysis workflow
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
news
Epstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
news
Identification of antibodies to target the NA globular head domain
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
news
Pancreatic cancer initiates an immune system response
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
article
Addressing the grand challenge of global access to vaccines
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
article
Rare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
article
Antibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
news
Could long Covid be solved by autoantibodies?
Swiss researchers have found a new class of 'good autoantibodies', which are associated with a favourable course and lower risk of long-Covid.
news
Uncovering the first FDA-approved drug for Ebola virus infection
US scientists have outlined the structure and function of the first FDA approved drug for the Ebola virus.
news
AI tools aid the discovery of super tight-binding antibodies
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
news
SARS-CoV-2 antibodies can bind to two viral targets at once
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
article
Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.